Financial Performance - The company reported research and development revenue of $6,707,000 for the three months ended March 31, 2025, representing a 6.0% increase from $6,326,000 in the same period of 2024[115]. - Gross profit for the same period was $3,168,000, with a gross margin of 47.2%, up from a gross profit of $2,945,000 and a margin of 46.6% in 2024[101]. - The operating loss decreased to $896,000 in Q1 2025 from $2,143,000 in Q1 2024, indicating improved operational efficiency[114]. - The company achieved a net income of $2,897,000 in Q1 2025, a significant turnaround from a net loss of $3,205,000 in Q1 2024, reflecting a change of $6,102,000[114]. - General and administrative expenses decreased by 20.1% to $4.1 million for the three months ended March 31, 2025, compared to $5.1 million in 2024[119]. - The company reported a net income of $2.9 million for the three months ended March 31, 2025, compared to a net loss of $3.2 million in 2024[126]. - Adjusted EBITDA for the three months ended March 31, 2025, was $(694) thousand, an improvement from $(1,857) thousand in 2024[126]. - The company had approximately $14.1 million in cash as of March 31, 2025, with an accumulated deficit of approximately $45.3 million[127]. - Net cash provided by financing activities increased to approximately $10.4 million for the three months ended March 31, 2025, compared to $8.0 million in 2024[137]. Contracts and Funding - The company has received a new contract with BARDA, providing up to $150 million in funding, including an initial award of approximately $54.9 million for clinical validation of the DeepView System[95]. - The new PBS BARDA Contract has a total value of up to approximately $150.0 million, with a base phase valued at $54.9 million[128]. - The company has received a $4.9 million grant from MTEC, intended to support military battlefield burn evaluation, with funding dependent on achieving various milestones[96]. - The company entered into a Loan and Security Agreement allowing it to borrow up to $15.0 million, with an initial drawdown of $8.5 million[129]. Clinical Studies and Product Development - The company initiated a pivotal clinical study in December 2023, enrolling 267 patients by the end of 2024, including 42 pediatric patients from burn centers and emergency departments[93]. - The DeepView System is expected to generate revenue through a software as a medical device (SaMD) model and an imaging device component once commercialized[97]. Company Structure and Operations - The company began trading on the Nasdaq under the symbols "MDAI" and "MDAIW" following the completion of a business combination on September 12, 2023[99]. - The company is highly dependent on U.S. governmental contracts for revenue, which may lead to variability in financial results based on the timing and amount of awards[106]. - One customer, a U.S. government agency, represents the majority of the company's research and development revenue and accounts receivable[155]. - The company has no off-balance sheet arrangements during the reported periods[143]. - The company is classified as an emerging growth company, allowing for an extended transition period for adopting new accounting standards[147]. Financing and Investments - Avenue Financing includes warrant coverage of 8.5% of the total funding commitment, with an exercise price based on a five-day average price of $1.66[140]. - Spectral IP, a wholly-owned subsidiary, received a $1.0 million investment for developing artificial intelligence intellectual property, structured as a note payable with an 8% interest rate[141]. - The Spectral IP Note was amended to reduce the interest rate from 8% to 4% and extend the term to March 18, 2026, with a conversion feature allowing for shares exchange[142]. - As of March 31, 2025, there were no outstanding obligations under the Spectral IP Note after full conversion into 540,996 shares[142]. - The company maintains a significant amount of cash, with interest rates on current borrowings at Prime plus 5.25%[152]. Economic Factors - Inflationary pressures may adversely affect the company's gross margin and operational results if costs continue to rise significantly[156].
ROSECLIFF ACQU(RCLF) - 2025 Q1 - Quarterly Report